Composite Fiber Structures with Antiproliferative Agents Exhibit Advantageous Drug Delivery and Cell Growth Inhibition In Vitro
Authors:
Open Access
- 1 January 2011
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 100 (1) , 133-149
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Long-term in vitro study of paclitaxel-eluting bioresorbable core/shell fiber structuresJournal of Controlled Release, 2008
- Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid)Molecular Cancer Therapeutics, 2007
- A Ras Inhibitor Tilts the Balance between Rac and Rho and Blocks Phosphatidylinositol 3-Kinase–Dependent Glioblastoma Cell MigrationCancer Research, 2006
- Biodegradable Injectable In Situ Depot‐Forming Drug Delivery SystemsMacromolecular Bioscience, 2006
- Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosisMolecular Cancer Therapeutics, 2006
- Physical characterization of controlled release of paclitaxel from the TAXUS™ Express2™ drug‐eluting stentJournal of Biomedical Materials Research Part A, 2004
- Prenyl-binding domains: potential targets for Ras inhibitors and anti-cancer drugsSeminars in Cancer Biology, 2004
- Poly(sebacic acid‐co‐ricinoleic acid) biodegradable carrier for paclitaxel: In vitro release and in vivo toxicityJournal of Biomedical Materials Research Part A, 2004
- Farnesyl Derivatives of Rigid Carboxylic Acids - Inhibitors of ras-Dependent Cell GrowthJournal of Medicinal Chemistry, 1995
- Quantitative Analysis of the Complex between p21 and the Ras-binding Domain of the Human Raf-1 Protein KinaseJournal of Biological Chemistry, 1995